|  |  |
| --- | --- |
|   Alexia LETIERCESENIOR BIOSTATISTICIAN, PhD. 18 years of experience  |  Une image contenant personne, mur, souriant, posant  Description générée automatiquement  |
| Address: 7 avenue Montaigne 91420 MORANGIS - FRANCE | e-mail: alexia.letierce@qualitystat.fr Phone: 33.6.84.90.56.64  |

####  PROFESSIONAL EXPERIENCES

|  |  |
| --- | --- |
| **From March 2020** | **Independent biostatistician**, self-employed, QualityStat.Statistical consulting and analyses for medical sciences.* Q2 2020: Conservatoire National des Arts et Métiers, Paris: analysis of a questionnaire on Quality of Life in workers
* Q2-Q3 2020, collaboration with Dr K. Alswat to write a manuscript on patients who received liver transplant for autoimmune hepatitis, publication ref 50
* July 2020-June 2021: statistician at BMS, Market Access team: oncology, cell therapy. Oversight of an external programming team. Use of mixture cure-models and propensity score methods
* Q3 2021-Q1 2022, Cegedim: analysis of Real World data in patients with COPD
* Q3-Q4 2021, Vitalaire/Orkyn: analysis of data from non-invasive ventilation machines. 4 Abstracts at the CPLF 2022 (congress of French Speaking Pneumologists)
* From May 2021, KBP-ESCAP 2020 study, epidemiological study in patients with lung cancer: in charge of the whole programming and statistical activities, contribution to manuscripts, member of the Scientific Committee. 2 Abstracts at the CPLF 2022 (congress of French Speaking Pneumologists)
* Q3 2021-Q3 2022: Septodont, 2 post marketing clinical follow-up studies, from set-up to analysis and clinical report
* From Q3 2021, IPSEN: statistician for the Data Monitoring Committee (DMC) on a product in endocrinology
* From Q3 2021: statistical support for Eclevar – observational studies on medical devices
 |

|  |  |
| --- | --- |
| **April 2014 – Feb 2020** | **Senior Biostatistician at Sanofi R&D** in Paris Area, France- As a Project biostatistician in Global Medical Affairs: Strategic role with clinicians in the cardiovascular (CV) area to define the study designs (literature review, realization of simulations in R to help decision).Coordination of the activity of junior statisticians on 10 studies, observational and interventional. Contribution to/review of protocols, statistical analysis plans and reports. Contribution to posters and manuscripts (SAS programming and editing): see list of publications below, ref 27-29; 31-48. Collaborations with external companies and review KOLs. Work in English with teams in the USA and China.Preparation of an FDA submission for a new drug application: coordination of electronic clinical data submission activities, scientific contribution to the dossier.- As a methodologist: supervision of four students at the Master level in statistics on methods for non-interventional studies, development of SAS programs for seamless designs. |

|  |  |
| --- | --- |
| **Sept 2011 - March 2014** | **Senior Biostatistician at Cegedim Strategic Data - Medical Research, Paris Area, France**Writing of statistical analysis plans, programming with SAS and R, writing of commented statistical reports in various therapeutic areas: oncology, hypertension, hypercholesterolemia, dermatology.Pharmaco-epidemiology studies, drug utilization studies, disease management studies. Prospective and retrospective designs, analysis of Electronic Medical Records (EMR).Realization of multivariate models (logistic, Cox, Markov chain). Publications: ref. 24 and 25.Work on procedures and quality improvement. Training and supervision of junior statisticians in France and subsidiaries. |

|  |  |
| --- | --- |
| **2006-2011** | **Biostatistician at the Clinical Research Unit of Bicêtre University Hospital**, AP-HP, Kremlin-Bicêtre (94). Director: Pr Laurent Becquemont. Data-management and biostatistics: Proofreading of protocols, Calculation of sample size, Randomization, Realization of CRFs and eCRF, submission of CCTIRS and CNIL, Statistical analysis with SAS and R, writing of the report of statistical analysis, contribution to the scientific publications and to grant applications. Various therapeutic areas: critical care, rare inflammatory diseases, endocrinology, psychiatry, hepatology. Methodological and statistical advice to physicians. Supervision of a data-manager and trainees of students in Public Health.Publications: ref. 4-23 ;26 ; 49 |

|  |  |
| --- | --- |
| **2004-2006** | **Post-doctoral fellowship in Biostatistics** at INSERM U1018 (French Institute for Health and Medical research), Villejuif (94). Development of statistical methods for the analysis of non-inferiority clinical trials in the field of HIV. |

|  |  |
| --- | --- |
| **2002-2004** | **Teaching assistant** at Paris V University in Epidemiology and Mathematics. |

|  |  |
| --- | --- |
| **2000-2003** | **PhD Student in Biostatistics**, INSERM U 1018, Villejuif (94)."Statistical methods for the comparison of two treatments in terms of efficacy and toxicity in oncology clinical trials." Keywords: clinical trial, oncology, efficacy, toxicity, bivariate data, order hypotheses, copula models, estimation of P (X <Y), Weibull's law. Thesis director: Pascale Tubert-Bitter (DR INSERM U 1018).Publications: ref. 1-3.Main manuscript from the thesis (ref. 1) awarded by the Norbert Marx Award by the French Society of Statistics in 2003. |

####  EDUCATION

####  CONTINUOUS EDUCATION

|  |  |
| --- | --- |
| **2019** | Training in East®: sample size calculation for multi-stage multi-arm trials (1 day) |
| **2017-2018** | Personal development training (4 days) |
| **2015** | Observational Clinical Research for Real World Evidence (2 days) |
| **2014** | Management of multiplicity in clinical trials (1 day) |
| **2012** | Mixed Generalized Linear Models, SAS Pharma Club Day |
| **2011** | Training seminar "Adaptive Testing", Univ. Paris V (2 days) |
| **2010** | SAS Level 1 Macro Language Training at SAS Institute (2 days) |

#### EDUCATION AT UNIVERSITY

|  |  |
| --- | --- |
| **2003** | PhD in Biostatistics, Paris XI University |
| **1999** | Pre-doctorate degree in Biostatistics, Montpellier II University |
| **1997-1998** | MSc in Mathematics, Lille I University |
| **1994-1996** | Two-year undergraduate intensive course in mathematics and physics (Maths Sup, Maths Spé M) |
| **1993** | High School Diploma, major in Science |

#### PROFESSIONAL SKILLS

|  |  |
| --- | --- |
| **Statistical softwares** | SAS (Base and Macro language), R, N'Query, East, MedCalcCleanweb (for CRF design and data-management) |
| **Office** | Word, Excel, PowerPoint |
| **Languages** | Fluent in professional English (working in English daily), German (basics),French (mother tongue) |

#### OTHER PROFESSIONAL ACTIVITIES

|  |  |
| --- | --- |
| **2019-2021** | Treasurer of the international Statistics & Biopharmacy congress [SNB 2022](http://www.snb2022.paris/) |
| **2021 and 2019** | President of Norbert Marx Award (on behalf of the French Society of Statistics - SFdS)  |
| **2015-2017** | Treasurer of the international congress statistical Methods in Biopharmacy 2017 |

####

#### PUBLICATIONS

1. **Letierce A**, Tubert-Bitter P, Kramar A, Maccario J. Two-treatment comparison based on joint toxicity and efficacy ordered alternatives in cancer trials. *Stat Med*. 2003 Mar 30;22(6):859-68. PubMed PMID: 12627405. Norbert Marx Award by French Society of Statistics (SFdS) in 2003.
2. Dellatolas G, De Agostini M, Curt F, Kremin H, **Letierce A**, Maccario J, Lellouch J. Manual skill, hand skill asymmetry, and cognitive performances in young children. *Laterality*. 2003 Oct;8(4):317-38. PubMed PMID: 15513229.
3. Tubert-Bitter P, **Letierce A**, Bloch DA, Kramar A. A nonparametric comparison of the effectiveness of treatments: a multivariate toxicity-penalized approach. *J Biopharm Stat.* 2005;15(1):129-42. PubMed PMID: 15702609.
4. Becquemont L, Neuvonen M, Verstuyft C, Jaillon P, **Letierce A**, Neuvonen PJ, Funck-Brentano C. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. *Clin Pharmacol Ther*. 2007 May;81(5):679-84. Epub 2007 Feb 14. PubMed PMID: 17301736.
5. Dommergues JP, **Letierce A**, Descots C, Debray D. [Medical follow-up, everyday life and actual experience of young adults after liver transplantation in childhood]. *Arch Pediatr*. 2008 Jun;15(5):855-6. doi:10.1016/S0929-693X(08)71940-7. French. PubMed PMID: 18582779.
6. Quteineh L, Verstuyft C, Durrbach A, **Letierce A**, Ferlicot S, Charpentier B, Becquemont L. Impact of VKORC1 haplotypes on long-term graft function in kidney transplantation. *Transplantation*. 2008 Sep 27;86(6):779-83. doi:10.1097/TP.0b013e31818376c7. PubMed PMID: 18813101.
7. Quteineh L, Verstuyft C, Furlan V, Durrbach A, **Letierce A**, Ferlicot S, Taburet AM, Charpentier B, Becquemont L. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. *Basic* *Clin Pharmacol Toxicol*. 2008 Dec;103(6):546-52. doi:10.1111/j.1742-7843.2008.00327.x. PubMed PMID: 19067682.
8. Dommergues JP, **Letierce A**, Bernard O, Debray D. [Medical follow-up, personal experiences and everyday life of young adults after liver transplantation during childhood]. *Bull Acad Natl Med*. 2008 Nov;192(8):1641-54; discussion 1654-6. Review. French. PubMed PMID: 19445378.
9. Auroux M, Volteau M, Ducot B, Wack T, **Letierce A**, Meyer L, Mayaux MJ. Progeny's mental aptitudes in man: relationship with parental age at conception and with some environmental factors. *C R Biol.* 2009 Jul;332(7):603-12. doi: 10.1016/j.crvi.2009.02.008. Epub 2009 Apr 7. PubMed PMID: 19523600.
10. Corruble E, Chouinard VA, **Letierce A**, Gorwood PA, Chouinard G. Is DSM-IV bereavement exclusion for major depressive episode relevant to severity and pattern of symptoms? A case-control, cross-sectional study. *J Clin Psychiatry*. 2009 Aug;70(8):1091-7. doi: 10.4088/JCP.08m04475. Epub 2009 Jun 30. PubMed PMID: 19573493.
11. Perrin L, **Letierce A**, Guitton C, Tran TA, Lambert V, Koné-Paut I. Comparative study of complete versus incomplete Kawasaki disease in 59 pediatric patients. *Joint Bone Spine.* 2009 Oct;76(5):481-5. doi: 10.1016/j.jbspin.2008.11.015. Epub 2009 Oct 6. PubMed PMID: 19811939.
12. Ferlicot S, Vernochet A, Romana S, Ortin-Serrano M, **Letierce A**, Brégerie O, Durrbach A, Guettier C. Microchimerism in renal allografts: clinicopathological associations according to the type of chimeric cells. *Histopathology*. 2010 Jan;56(2):188-97. doi: 10.1111/j.1365-2559.2009.03466.x. PubMed PMID: 20102397.
13. Dommergues JP, **Letierce A**, Gravereau L, Plainguet F, Bernard O, Debray D. Current lifestyle of young adults after liver transplantation during childhood*. Am J Transplant*. 2010 Jul;10(7):1634-42. doi: 10.1111/j.1600-6143.2010.03054.x. Epub 2010 Mar 23. PubMed PMID: 20346060.
14. Carbonell N, Verstuyft C, Massard J, **Letierce A**, Cellier C, Deforges L, Saliba F, Delchier JC, Becquemont L. CYP2C9\*3 Loss-of-Function Allele Is Associated With Acute Upper Gastrointestinal Bleeding Related to the Use of NSAIDs Other Than Aspirin. *Clin Pharmacol Ther*. 2010 Jun;87(6):693-8. doi: 10.1038/clpt.2010.33. Epub 2010 May 5. PubMed PMID: 20445534.
15. Kondi A, Hentgen V, Piram M, **Letierce A**, Guillaume-Czitrom S, Koné-Paut I. Validation of the new paediatric criteria for the diagnosis of familial Mediterranean fever: data from a mixed population of 100 children from the French reference centre for auto-inflammatory disorders. *Rheumatology (Oxford).* 2010 Nov;49(11):2200-3. doi: 10.1093/rheumatology/keq252. Epub 2010 Aug 5. PubMed PMID: 20688806.
16. Koné-Paut I, Darce-Bello M, Shahram F, Gattorno M, Cimaz R, Ozen S, Cantarini L, Tugal-Tutktun I, Assaad-Khalil S, Hofer M, Kuemmerle-Deschner J, Benamour S, Al Mayouf S, Pajot C, Anton J, Faye A, Bono W, Nielsen S, **Letierce A**, Tran TA; PED-BD International Expert Committee. Registries in rheumatological and musculoskeletal conditions. Paediatric Behçet's disease: an international cohort study of 110 patients. One-year follow-up data. *Rheumatology (Oxford).* 2011 Jan;50(1):184-8. doi: 10.1093/rheumatology/keq324. Epub 2010 Oct 29. PubMed PMID:21036877.
17. Michelon H, König J, Durrbach A, Quteineh L, Verstuyft C, Furlan V, Ferlicot S, **Letierce A**, Charpentier B, Fromm MF, Becquemont L. SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. *Pharmacogenomics*. 2010 Dec;11(12):1703-13. doi: 10.2217/pgs.10.132. PubMed PMID: 21142914.
18. Monnet X, **Letierce A**, Hamzaoui O, Chemla D, Anguel N, Osman D, Richard C, Teboul JL. Arterial pressure allows monitoring the changes in cardiac output induced by volume expansion but not by norepinephrine. *Crit Care Med*. 2011 Jun;39(6):1394-9. doi: 10.1097/CCM.0b013e31820edcf0. PubMed PMID: 21336124.
19. Kamenicky P, Blanchard A, Frank M, Salenave S, **Letierce A**, Azizi M, Lombès M, Chanson P. Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity. *J Clin Endocrinol Metab*. 2011 Jul;96(7):2127-35. doi: 10.1210/jc.2011-0078. Epub 2011 Apr 20. PubMed PMID: 21508131.
20. Kamenický P, Blanchard A, Gauci C, Salenave S, **Letierce A**, Lombès M, Brailly-Tabard S, Azizi M, Prié D, Souberbielle JC, Chanson P. Pathophysiology of renal calcium handling in acromegaly: what lies behind hypercalciuria? *J Clin Endocrinol Metab*. 2012 Jun;97(6):2124-33. doi: 10.1210/jc.2011-3188. Epub 2012 Apr 10. PubMed PMID: 22496496.
21. Fournier-Charrière E, Tourniaire B, Carbajal R, Cimerman P, Lassauge F, Ricard C, Reiter F, Turquin P, Lombart B, **Letierce A**, Falissard B. EVENDOL, a new behavioral pain scale for children ages 0 to 7 years in the emergency department: design and validation. *Pain*. 2012 Aug;153(8):1573-82. doi: 10.1016/j.pain.2012.02.024. Epub 2012 May 19. PubMed PMID: 22609430.
22. Durand P, Debray D, Kolaci M, Bouligand J, Furlan V, Fabre M, **Letierce A**, Verstuyft C, Becquemont L. Tacrolimus dose requirement in pediatric liver transplantation: influence of CYP3A5 gene polymorphism. *Pharmacogenomics*. 2013 Jul;14(9):1017-25. doi: 10.2217/pgs.13.87. PubMed PMID: 23837476.
23. Saliba F, Camus C, Durand F, Mathurin P, **Letierce A**, Delafosse B, Barange K, Perrigault PF, Belnard M, Ichaï P, Samuel D. Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. *Ann Intern Med*. 2013 Oct 15;159(8):522-31. doi:10.7326/0003-4819-159-8-201310150-00005. PubMed PMID: 24126646.
24. Cotté FE, Benhaddi H, Duprat-Lomon I, Doble A, Marchant N, **Letierce A**, Huguet M. Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries*. Clin Ther*. 2014 Sep 1;36(9):1160-8. doi: 10.1016/j.clinthera.2014.07.016. Epub 2014 Aug 21. PubMed PMID: 25151574.
25. **Letierce A**, Jouaville SL, Boutmy E. Understanding Real Life Treatment Patterns Among Patients With Hypertension: A Markov Model. *Value Health*. 2014 Nov;17(7):A566. doi: 10.1016/j.jval.2014.08.1882. Epub 2014 Oct 26. PubMed PMID: 27201878. (Poster)
26. Cros J, Sbidian E, Posseme K, **Letierce A**, Guettier C, Benoît G, Ferlicot S. Nestin expression on tumour vessels and tumour-infiltrating macrophages define a poor prognosis subgroup of pt1 clear cell renal cell carcinoma. *Virchows Arch*. 2016 Sep;469(3):331-7. doi: 10.1007/s00428-016-1973-2. Epub 2016 Jun 17. PubMed PMID: 27311769.
27. Cariou B, Leiter LA, Müller-Wieland D, Bigot G, Colhoun HM, Del Prato S, Henry RR, Tinahones FJ, **Letierce A**, Aurand L, Maroni J, Ray KK, Bujas-Bobanovic M. Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial. *Diabetes Metab*. 2017 Oct;43(5):453-459. doi:10.1016/j.diabet.2017.01.004. Epub 2017 Mar 24. PubMed PMID: 28347654.
28. Müller-Wieland D, Leiter LA, Cariou B, **Letierce A**, Colhoun HM, Del Prato S, Henry RR, Tinahones FJ, Aurand L, Maroni J, Ray KK, Bujas-Bobanovic M. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. *Cardiovasc Diabetol.* 2017 May 25;16(1):70. doi:10.1186/s12933-017-0552-4. PubMed PMID: 28545518; PubMed Central PMCID: PMC5445362.
29. Leiter LA, Müller-Wieland D, Baccara-Dinet MT, **Letierce A**, Samuel R, Cariou B. Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials. *Diabet Med.* 2018 Jan;35(1):121-130. doi: 10.1111/dme.13450. Epub 2017 Aug 31. PubMed PMID: 28799203; PubMed Central PMCID: PMC5763418.
30. Martelli C, Petillion A, Brunet-Lecomte M, Miranda Marcos R, Chanraud S, Amirouche A, **Letierce A**, Kostogianni N, Lemaitre H, Aubin HJ, Blecha L, Reynaud M, Martinot JL, Benyamina A. Neuropsychological Impairment in Detoxified Alcohol-Dependent Subjects with Preserved Psychosocial Functioning. *Front Psychiatry*. 2017 Sep 29;8:193. doi: 10.3389/fpsyt.2017.00193. eCollection 2017. PubMed PMID: 29033861; PubMed Central PMCID: PMC5626858.
31. Ray KK, Leiter LA, Müller-Wieland D, Cariou B, Colhoun HM, Henry RR, Tinahones FJ, Bujas-Bobanovic M, Domenger C, **Letierce A**, Samuel R, Del Prato S. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. *Diabetes Obes Metab*. 2018 Jun;20(6):1479-1489. doi: 10.1111/dom.13257. Epub 2018 Mar 23. PubMed PMID: 29436756; PubMed Central PMCID: PMC5969299.
32. Henry RR, Müller-Wieland D, Taub PR, Bujas-Bobanovic M, Louie MJ, **Letierce A**, Ginsberg HN. Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. *Diabetes Obes Metab*. 2018 Jul;20(7):1632-1641. doi: 10.1111/dom.13273. Epub 2018 Mar 25. PubMed PMID: 29493859; PubMed Central PMCID: PMC6033097.
33. Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A, Louie MJ, Koren A, **Letierce A**, Mandel J, Banach M. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. *Kidney Int.* 2018 Jun;93(6):1397-1408. doi: 10.1016/j.kint.2017.12.011. Epub 2018 Mar 8. PubMed PMID: 29526502.
34. Ginsberg HN, Farnier M, Robinson JG, Cannon CP, Sattar N, Baccara-Dinet MT, **Letierce A**, Bujas-Bobanovic M, Louie MJ, Colhoun HM. Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. *Diabetes Ther*. 2018 Jun;9(3):1317-1334. doi: 10.1007/s13300-018-0439-8. Epub 2018 May 19. PubMed PMID: 29779195; PubMed Central PMCID: PMC5984942.
35. Ganda OP, Plutzky J, Sanganalmath SK, Bujas-Bobanovic M, Koren A, Mandel J, **Letierce A**, Leiter LA. Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials. *Diabetes Obes Metab*. 2018 Oct;20(10):2389-2398. doi: 10.1111/dom.13384. Epub 2018 Jul 2. PubMed PMID: 29802688; PubMed Central PMCID: PMC6175384.
36. Taskinen MR, Del Prato S, Bujas-Bobanovic M, Louie MJ, **Letierce A**, Thompson D, Colhoun HM. Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. *Atherosclerosis*. 2018 Sep;276:124-130. doi: 10.1016/j.atherosclerosis.2018.07.017. Epub 2018 Jul 21. PubMed PMID: 30059843.
37. Leiter LA, Tinahones FJ, Karalis DG, Bujas-Bobanovic M, **Letierce A**, Mandel J, Samuel R, Jones PH. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. *Diabet Med*. 2018 Dec;35(12):1742-1751. doi: 10.1111/dme.13817. Epub 2018 Oct 9. PubMed PMID: 30183102.
38. Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Eckel RH, Cannon CP, Lee LV, Bessac L, Pordy R, **Letierce A**, Ray KK. Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. *J Am Heart Assoc*. 2018 Sep 18;7(18):e009221. doi: 10.1161/JAHA.118.009221. PubMed PMID: 30371190; PubMed Central PMCID: PMC6222947.
39. Bruckert E, Kereiakes DJ, Koren MJ, Louie MJ, **Letierce A**, Miller K, Cannon CP. PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab. *J Clin Lipidol.* 2019 Apr 10. pii: S1933-2874(19)30075-3. doi:10.1016/j.jacl.2019.04.005. [Epub ahead of print] PubMed PMID: 31076261.
40. Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, **Letierce A**, Cannon CP. [Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.](https://www.ncbi.nlm.nih.gov/pubmed/31349086) *Atherosclerosis*. 2019 Jul 12;288:85-93. doi: 10.1016/j.atherosclerosis.2019.07.008. [Epub ahead of print] PMID:31349086
41. [Raal FJ](https://www.ncbi.nlm.nih.gov/pubmed/?term=Raal%20FJ%5BAuthor%5D&cauthor=true&cauthor_uid=31377052), [Tuomilehto J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tuomilehto%20J%5BAuthor%5D&cauthor=true&cauthor_uid=31377052), [Sposito AC](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sposito%20AC%5BAuthor%5D&cauthor=true&cauthor_uid=31377052), [Fonseca FA](https://www.ncbi.nlm.nih.gov/pubmed/?term=Fonseca%20FA%5BAuthor%5D&cauthor=true&cauthor_uid=31377052), [Averna M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Averna%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31377052), [Farnier M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Farnier%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31377052), [Santos RD](https://www.ncbi.nlm.nih.gov/pubmed/?term=Santos%20RD%5BAuthor%5D&cauthor=true&cauthor_uid=31377052), [Ferdinand KC](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ferdinand%20KC%5BAuthor%5D&cauthor=true&cauthor_uid=31377052)8, [Wright RS](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wright%20RS%5BAuthor%5D&cauthor=true&cauthor_uid=31377052), [Navarese EP](https://www.ncbi.nlm.nih.gov/pubmed/?term=Navarese%20EP%5BAuthor%5D&cauthor=true&cauthor_uid=31377052), [Lerch DM](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lerch%20DM%5BAuthor%5D&cauthor=true&cauthor_uid=31377052), [Louie MJ](https://www.ncbi.nlm.nih.gov/pubmed/?term=Louie%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=31377052), [Lee LV](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20LV%5BAuthor%5D&cauthor=true&cauthor_uid=31377052), [**Letierce A**](https://www.ncbi.nlm.nih.gov/pubmed/?term=Letierce%20A%5BAuthor%5D&cauthor=true&cauthor_uid=31377052), [Robinson JG](https://www.ncbi.nlm.nih.gov/pubmed/?term=Robinson%20JG%5BAuthor%5D&cauthor=true&cauthor_uid=31377052). Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. [*J Clin Lipidol.*](https://www.ncbi.nlm.nih.gov/pubmed/31377052)2019 Jun 29. pii: S1933-2874(19)30226-0. doi: 10.1016/j.jacl.2019.06.006. [Epub ahead of print]
42. Goodman SG, Aylward PE, Szarek M, Chumburidze V, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Hanotin C, Harrington RA, Jukema JW, Kedev S, **Letierce A**, Moryusef A, Pordy R, Ramos López GA, Roe MT, Viigimaa M, White HD, Zeiher AM, Steg PG, Schwartz GG; ODYSSEY OUTCOMES Committees and Investigators. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. *J Am Coll Cardiol*. 2019 Sep 3;74(9):1177-1186. doi: 10.1016/j.jacc.2019.07.015. PMID: 31466614.
43. Ray KK, Del Prato S, Müller-Wieland D, Cariou B, Colhoun HM, Tinahones FJ, Domenger C, **Letierce A**, Mandel J, Samuel R, Bujas-Bobanovic M, Leiter LA. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. *Cardiovasc Diabetol*. 2019 Nov 9;18(1):149. doi: 10.1186/s12933-019-0951-9. PMID: 31706300; PMCID: PMC6842201.
44. Bielory L, Gross GN, **Letierce A**, Melas-Melt L, Lucio L. Ocular symptoms improvement from intranasal triamcinolone compared with placebo and intranasal fluticasone propionate: A meta-analysis. *Ann Allergy Asthma Immunol*. 2020 Jun;124(6):616-621.e3. doi: 10.1016/j.anai.2020.01.012. Epub 2020 Jan 28. PMID: 32004698.
45. Colhoun HM, Leiter LA, Müller-Wieland D, Cariou B, Ray KK, Tinahones FJ, Domenger C, **Letierce A**, Israel M, Samuel R, Del Prato S. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. *Cardiovasc Diabetol*. 2020 Feb 8;19(1):14. doi: 10.1186/s12933-020-0991-1. PMID: 32035487; PMCID: PMC7007683.
46. Vallejo-Vaz AJ, Leiter LA, Del Prato S, Taskinen MR, Müller-Wieland D, Bujas-Bobanovic M, **Letierce A**, Mandel J, Samuel R, Ray KK. Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. Eur J Prev Cardiol. 2020 Oct;27(15):1663-1674. doi: 10.1177/2047487320905185. Epub 2020 Feb 23. PMID: 32089006; PMCID: PMC7549294.
47. Langslet G, Hovingh GK, Guyton JR, Baccara-Dinet MT, **Letierce A**, Manvelian G, Farnier M. Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study*. Cardiovasc* *Drugs Ther*. 2020 Aug;34(4):515-523. doi: 10.1007/s10557-020-06984-0. PMID: 32363493; PMCID: PMC7334259.
48. Gaudet D, López-Sendón JL, Averna M, Bigot G, Banach M, **Letierce A**, Loy M, Samuel R, Manvelian G, Batsu I, Henry P. Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. *Eur J Prev Cardiol*. 2020 Nov 22:zwaa097. doi: 10.1093/eurjpc/zwaa097. Epub ahead of print. PMID: 33624041.
49. [Anne Filleron](https://pubmed.ncbi.nlm.nih.gov/?term=Filleron+A&cauthor_id=33734346), [Tu Anh Tran](https://pubmed.ncbi.nlm.nih.gov/?term=Tran+TA&cauthor_id=33734346), [Audrey Hubert](https://pubmed.ncbi.nlm.nih.gov/?term=Hubert+A&cauthor_id=33734346), [**Alexia Letierce**](https://pubmed.ncbi.nlm.nih.gov/?term=Letierce+A&cauthor_id=33734346), [Guillaume Churlaud](https://pubmed.ncbi.nlm.nih.gov/?term=Churlaud+G&cauthor_id=33734346), [Isabelle Koné-Paut](https://pubmed.ncbi.nlm.nih.gov/?term=Kon%C3%A9-Paut+I&cauthor_id=33734346), [David Saadoun](https://pubmed.ncbi.nlm.nih.gov/?term=Saadoun+D&cauthor_id=33734346), [Renaud Cezar](https://pubmed.ncbi.nlm.nih.gov/?term=Cezar+R&cauthor_id=33734346), [Pierre Corbeau](https://pubmed.ncbi.nlm.nih.gov/?term=Corbeau+P&cauthor_id=33734346), [Michelle Rosenzwajg](https://pubmed.ncbi.nlm.nih.gov/?term=Rosenzwajg+M&cauthor_id=33734346). Regulatory T cell/Th17 balance in the pathogenesis of pediatric Behçet disease. *Rheumatology (Oxford),* 2021 Mar 18; keab253 doi: 10.1093/rheumatology/keab253
50. Khalid Alswat, Elvy Soliman; Isam Salih, Ahmed Bashmail; **Alexia Letierce**; Ali Benmousa, Saad Alghamdi, Khalid I Bzeizi, Saleh A Alqahtani, Mohamed Shawkat; Dieter C Broering, Waleed K Al-hamoudi. Long Term Outcomes of Liver Transplantation for Patients with Autoimmune Hepatitis. To be published in *Transplantation* Proceedings, 2021.